Navigation Links
RIPE Pilot Study Suggests Resveratrol May Improve Cognitive Function In The Elderly
Date:11/27/2012

SAN DIEGO, Nov. 27, 2012 /PRNewswire/ -- Findings from the "Resveratrol for Improved Performance in Elders" (RIPE) trial were presented last week at the 65th Annual Scientific Meeting of The Gerontological Society of America, which was hosted at the San Diego Convention Center from November 14 – 18.  The conference offered more than 400 scientific sessions to over 4,000 leaders in the field of aging from around the world.

The RIPE pilot study, a double-blind, placebo-controlled trial conducted by researchers at the University of Florida in Gainesville, followed cognitively intact men and women who orally ingested Resveratrol (provided by Reserveage Organics) in either 300 mg/d or 1000 mg/d doses over a 90-day period. Cognitive assessments were made at baseline and at the end of the study (Day 90) using: Hopkins Verbal Learning Test (HVLT), Digits Forward and Backward (DFB), Controlled Oral Word Association (COWA), Trail Making Tests (TMT: A & B), Digit Symbol Copy number (DSCN), and Digit Symbol Substitution Test (DSST).

Compared to placebo, Resveratrol supplementation taken in the 1000 mg/d dose improved psychomotor (processing) speed and significantly increased hippocampal activation (increased blood flow to the brain). Resveratrol, a natural polyphenolic compound present in various dietary sources including peanuts, grapes, red wine, and Japanese knotweed, has demonstrated a wide range of physiological benefits in humans.

"Our findings are supportive of a short-term course of Resveratrol supplementation for enhancing psychomotor speed and increasing hippocampal activation. We also observed exciting trends suggesting memory was improved," said lead researcher Steve Anton, Ph.D.,** from the Dept. of Aging and Geriatric Research and Institute on Aging at the University of Florida. "The results are very promising and show that Resveratrol may have a predictable positive impact on cognitive function in older adults."

The RIPE study, summarized in a poster presentation was supported by the McKnight Brain Research Foundation at the University of Florida; the NIH/NIA Claude D. Pepper Center; and Thomas H. Maren Foundation. Reserveage Organics, which provided Resveratrol supplements for the study, is based in Gainesville, Florida.  
**Steve Anton, Ph.D. periodically serves as a consultant for Reserveage Organics.


'/>"/>
SOURCE Reserveage Organics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bluechiip Receives First Sales Order from ATCC after Completion of Successful Pilot Trial
2. In Pilot Study, a Peptide Controls Blood Sugar in People with Congenital Hyperinsulinism
3. Ocular Therapeutix Commences Pilot Phase II Travoprost Punctum Plug Study for the Treatment of Glaucoma
4. Systagenix begins pilot with ToolsGroup to optimise inventory levels
5. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
6. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
7. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
8. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
9. Shingles Vaccine is Safe, According to New Study
10. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
11. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has ... chances of acceptance to a residency in a United States hospital. Being accepted ... the U.S. , According to data released by the ECFMG®, every year, 50 ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon ... the signature product of her research center at Bio-Logic Aqua Research® Water Life ... and the greatest number of sufferers of blindness. “We think that Nature’s Tears® ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/21/2017)... ONTARIO, CANADA (PRWEB) , ... July 21, 2017 ... ... give insight into why concussion rates are on the rise, say researchers presenting ... Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
Breaking Medicine News(10 mins):